



Ministry of Health of the
Republic of Uzbekistan



Tashkent Medical
Academy



**Materials of International Scientific-Practical
Conference**

“Only English: Topical Issues of Healthcare”



**only
ENGLISH**

Tashkent

15 May, 2022



<i>Shamansurov Sh.Sh., Abdukadyrova I.K.</i> / Clinico-neurological characteristics of children with congenital and acquired neurosensory hearing loss.....	26
<i>Xasanova.Sh.A., Tadjiyev.B.M.</i> / Study clinical course - diagnostic criteria and features manifestations of COVID-19 in at risk patients.....	27
<i>Yuldosheva S.U., Bekchanova N.I.</i> / Hemostatic changes in patients with autoimmune thyroiditis	28

SURGERY

<i>Almuradova D.M., Turaeva Kh.Kh.</i> / The effectiveness of bevacizumab (AVASTIN) in the treatment of ovarian cancer.....	30
<i>Almuradova D.M., Yusupov A.A.</i> / Features of the diagnosis and treatment of locally advanced rectal cancer	31
<i>Ibragimov N.K., Kenjaev L.T., Juraqulov A.Q.</i> / Kallidinogenase (tissue kallikrien) in complex therapy in patients with isolated closed traumatic brain injury	32
<i>Ismoilov J.X., Almuradova D.M., Yusupov A.A., Qarlibaev A.O.</i> / The effectiveness of the rituximab+ABVD regimen in contrast to the standard ABVD regimen in the treatment of mixed cell type hodgkin's lymphoma.....	33
<i>Jumanazarova M.J., Sattarov O.T.</i> / The role and importance of videolaparoscopy in the surgical treatment of strangulated inguinal hernias	34
<i>Karimova F.D., Rakhmanova S.SH.</i> / Methods for determining pregnant women with a high infectious risk.....	35
<i>Khamdamov I.B.</i> / The strategy of choosing the method of hernia repair of the anterior abdominal wall in women of fertile age (experimental clinical study)	36
<i>Khamidov Kh.Kh.</i> / Immediate results of surgical cancer treatment of cardioesophageal zone	37
<i>Komilova D.K., Kayumova D.T.</i> / Thin endometrium ways to solve the problem	38
<i>Muftaydinova Sh.K., Buralkina N.A., Faizullin L.Z., Muminova Z.A., Asaturova A.V.</i> / Expression of the tyrosine kinase receptor (EPhA2) in the endometrium of patients with deep infiltrative endometriosis	39
<i>Muftaydinova Sh.K., Buralkina N.A., Muminova Z.A., Fayzullin L.Z.</i> / EPH receptors in cancer and endometriosis	39
<i>Mukumiva D.I., Almuradova D.M.</i> / To evaluate the effectiveness and toxicity of endocrine therapy in postmenopause breast cancer patients	40
<i>Muxamedova Z.R., Yuldasheva D.X.</i> / Comparative analysis of clinical signs in patients with covid-19 who suffer chronic viral hepatitis c.....	41
<i>Rakhimov O.U., Mukhammadsolikh Sh.B.</i> / Evaluation of clinical and economic efficiency of using gemogubka after cholecystectomy	42

EXPRESSION OF THE TYROSINE KINASE RECEPTOR (EPhA2) IN THE ENDOMETRIUM OF PATIENTS WITH DEEP INFILTRATIVE ENDOMETRIOSIS

Muftaydinova Sh.K., Buralkina N.A., Faizullin L.Z., Muminova Z.A., Asaturova A.V.

Tashkent medical academy, Tashkent, Uzbekistan

National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia, Moscow, Russia

Aim: to evaluate the nature of the expression of the EphA2 receptor in the endometrium of healthy women and in ectopic epithelial cells in deep infiltrative endometriosis.

Material and methods: A comparative study of the expression of EphA2 in ectopic endometrium in women with endometriosis, endometrial adenocarcinoma and in healthy women in different phases of the menstrual cycle was carried out.

Results: Immunochemical studies have shown that EphA2 is present in epithelial cells of the normal endometrium in the proliferative phase and practically absent in the secretory phase. In the epithelial cells of the infiltrative ectopic endometrium, the intensity of staining is significantly higher than in the normal endometrium of the proliferative phase and is comparable to the intensity of EphA2 expression in endometrial cancer cells.

Conclusion: The results of the study showed the presence of EphA2 overexpression in the epithelial cells of the infiltrative ectopic endometrium. Thus, in addition to the diagnostic value, the modulation of the activity of these receptors in endometriosis can serve as a target for therapy.

Literature:

1. Salem A. F., Wang S., Billet S., Chen J. F., Udompholkul P., Gambini L., Baggio C., Tseng H. R., Posadas E. M., Bhowmick N. A., and Pellicchia M. 2018; Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic PeptideDrug Conjugate. Journal of medicinal chemistry J Med Chem. 2018; 61(5): 2052-2061.

EPH RECEPTORS IN CANCER AND ENDOMETRIOSIS

Muftaydinova Sh.K., Buralkina N.A., Muminova Z.A., Fayzullin L.Z.

Tashkent medical academy, Tashkent, Uzbekistan

National Medical Research Center for Obstetrics, Gynecology and Perinatology Ministry of Health of Russia, Moscow, Russia

The mechanism of endometriosis development is complex and controlled by various factors, most of which are based on cell proliferation, tissue invasion, neovascularization and inhibition of apoptosis. In women with endometriosis, the frequency of malignant neoplasms of different localization is increased, which indicates the similarity of their pathogenesis and common environmental, molecular and genetic risk factors [1,2]. The presence of common characteristics of the development of ectopic endometrium, especially in deep infiltrative endometriosis, and cancer suggests not only the same pathogenesis mechanism, but also common therapy approaches. Therefore, it cannot be excluded that many factors used today as a target for cancer therapy may manifest themselves similarly in endometriosis. In this regard, ephrin receptors (Eph) are of particular